- Fee assured
- Verified this account
Dr Adamali’s main interests are in the management of patients with interstitial lung disease and COPD, its diagnoses and treatment. He is also interested in management of patients with inflammatory lung diseases such as bronchiectasis.
He has completed his education in Montreal (McGill University) and Dublin (University College Dublin). He subsequently completed his respiratory training in Dublin. He received a European Respiratory Society Fellowship which allowed him to work in the Royal Brompton Hospital, London.
At present he is actively working currently at the Bristol Interstitial Lung Disease (BILD) Service at the North Bristol Trust, where he is involved in the diagnosis and the management of idiopathic pulmonary fibrosis, hypersensitive pneumonitis, sarcoidosis, connective tissue (scleroderma, rheumatoid disease, sjogren disease) related interstitial lung disease, smoking related interstitial lung disease, pulmonary vasculitis and occupational and drug induced lung disorders.
Areas of interest
Dr Adamali’s main interests are in the management of patients with interstitial lung disease and COPD, its diagnoses and treatment. He is also interested in management of patients with asthma and inflammatory lung diseases such as bronchiectasis.
Dr Adamali is involved in the diagnosis and the management of idiopathic pulmonary fibrosis, hypersensitive pneumonitis, sarcoidosis, connective tissue (scleroderma, rheumatoid disease, sjogren disease) related interstitial lung disease, smoking related interstitial lung disease, pulmonary vasculitis and occupational and drug induced lung disorders.
Current NHS consultant posts held
Consultant Respiratory Physician with Specialist Interest in Interstitial Lung Disease
Bristol Interstitial Lung Disease (BILD) Service
North Bristol Lung Center
Southmead General Hospital,
Dr Adamali is currently involved in several clinical trials at Southmead Hospital. His focus is interstitial lung disease, understanding mechanisms and working with service provisions of these patients
Dr Adamali enjoys reading and travelling.
2011-2013 European Respiratory Society Fellowship
2012 American Thoracic Society Travel Award (San Francisco)
2008 American Thoracic Society Travel Award
2006 Irish Research Council for Science, Engineering and Technology, EMBARK Post-Graduate Scholarship
2006 Irish Lung Foundation Research Award
English, French, Gujrati, Urdu
Sharp C, Lamb H, Jordan N, Edwards A, Gunary R, Meek P, Millar AB, Kendall C, Adamali HDevelopment of tools to facilitate palliative and supportive care referral for patients with idiopathic pulmonary fibrosis.BMJ Support Palliat Care. 2017
Baggott C, Sharp C, Bhatt N, Plummeridge M, Adamali H. Lesson of the month 1: A cough that doesn't fit the mould.
Clin Med (Lond). 2015 Oct;15(5):492-4
Sharp C, Dodds N, Mayers L, Millar AB, Gunawardena H, Adamali H. The role of biologics in treatment of connective tissue disease-associated interstitial lung disease.
QJM. 2015 Jan 21. pii: hcv007.
Mason RH, Foley NM, Branley HM, Adamali HI, Hetzel M, Maher TM, Suntharalingam J. Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register.Thorax. 2014 Jan 30. doi: 10.1136/thoraxjnl-2013
Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, Abraham DJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Lindahl GE, Renzoni EA. Mucin 5B promoter polymorphism is associated with idiopathic
pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax. 2013; 68:436-41.
Adamali HI, Anwar M, Russell AM, Egan J. Non-pharmacological treatment of idiopathic pulmonary fibrosis. Curr Respir Care Rep. 2012; 1(4): 208-215.
Adamali HI, Maher TM. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther. 2012;6:261-71.
Adamali H, Armstrong ME, McLaughlin AM, Cooke G, McKone E, Costello CM, Gallagher CG, Leng L, Baugh JA, Fingerle-Rowson G, Bucala RJ, McLoughlin P, Donnelly SC. Macrophage migration inhibitory factor enzymatic activity, lung
inflammation, and cystic fibrosis. Am J Respir Crit Care Med. 2012;186:162-9.
Adamali HI, Judge EP, Healy D, Nolke L, Redmond KC, Bartosik W, McCarthy J, Egan JJ. International collobaration: a retrospective study examining the survival of Irishcitizens following lung transplantation in both the UK and Ireland. BMJ Open. 2012:
Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012;40(1):93-100
Egan JJ, Adamali HI, Lok SS, Stewart JP, Woodcock AA. Ganciclovir Antiviral Therapy in Advanced Idiopathic Pulmonary Fibrosis: An Open Pilot Study. PulmonaryMedicine, vol. 2011, Article ID 240805, 2011. doi:10.1155/2011/240805
Courses offered to GPs
Please liaise with Bristol Spire
- MB BCH BAO University College Dublin, Dublin, Ireland 2001
- BSC McGill University, Montreal Canada 1995
- MSC McGill University, Montreal, Canada 1996
- MRCPI Royal College of Physicians Ireland, Dublin, Ireland 2005
- MD University College Dublin, Dublin, Ireland 2011
- FRCP Royal College of Physicians London 2016
- European Respiratory Society Fellowship Royal Brompton Hospital 2011
Reference number 7034500
Details of entry to specialist register
- General Medical Council, 2011
Affiliations / memberships
Royal College of Physician UK
American Thoracic Society
European Respiratory Society
British Lung Foundation
British Thoracic Society
- Spire Bristol Hospital, BS6 6UT
- 17:00 - 20:00
- 0117 980 4000
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.